Article
Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia.
International immunopharmacology - 30 May 2024
Cheng Fang, Cui Zheng, Li Qiang, Chen Shi, Li Weiming, Zhang Yu
Abstract excerpt
BACKGROUND: Diminished bioavailability of imatinib in leukemic cells contributes to poor clinical response. We examined the impact of genetic polymorphisms of imatinib on the pharmacokinetics and clinical response in 190 patients with chronic myeloid leukaemia (CML). METHODS: Single nucleotide polymorphisms were genotyped using pyrophosphate sequencing. Plasma trough levels of imatinib were measured using liquid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
